A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer (NCT07310420)
Phase 1 Single-arm, Open-label, Multicenter Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in 2 Parallel Cohorts of Premenopausal Women With Early-stage and Advanced Hormone Receptor-positive (HR+) Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.
Who can join: Review the eligibility criteria below.
Location: Genesis Cancer and Blood Institute — Hot Springs, Arkansas
Age range: 18 Years to 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Genesis Cancer and Blood Institute — Hot Springs, Arkansas
- MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Cancer Centers of Florida — Ocoee, Florida
- Summit Cancer Care — Savannah, Georgia
- NorthShore University Health System - Evanston Hospital — Evanston, Illinois
- NorthShore University HealthSystem - Evanston Hospital — Evanston, Illinois
- Duly Health and Care — Lisle, Illinois
- Orchard Healthcare Research — Skokie, Illinois
- Springfield Clinic - The Cancer Center — Springfield, Illinois
- Profound Research LLC at Michigan Hematology and Oncology Consultants — Royal Oak, Michigan
- St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute) — Billings, Montana
- San Juan Oncology Associates — Farmington, New Mexico
- New York Oncology Hematology - Amsterdam Cancer Center — Amsterdam, New York
- Chelsea Medical Center at Mount Sinai — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Cleveland Clinic Foundation — Cleveland, Ohio
- The Mark H. Zangmeister Center-Mid Ohio Oncology/Hematology, Inc. — Columbus, Ohio
- St. Luke's University Health Network — Bethlehem, Pennsylvania
- Guthrie Medical Group — Sayre, Pennsylvania
- Oncology Consultants PA — Houston, Texas
📞 Contact the Study Coordinator
Phone: (888) 600-8116
Email: christine.fredericks@tersera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Breast Cancer
- RCT of CBD for Anxiety in Advanced Breast Cancer — Boston, Massachusetts
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer — Encinitas, California
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer — Springdale, Arkansas
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer — St Louis, Missouri
- Engage Psychosocial Intervention for Cancer Symptoms — Durham, North Carolina
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors — Duarte, California
Explore by condition: All Advanced Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.